Comparing four drug combinations for older or unfit AML patients
Part of Blood & lymphatic, Cancer clinical trials.
This trial compares four different combinations of targeted therapy and chemotherapy for people with newly diagnosed AML who cannot have standard intensive chemo. The goal is to see which combination works best safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with acute myeloid leukemia (AML) and not received any previous treatment for it, except possibly hydroxyurea or a small amount of cytarabine for emergency control.
- You are either 60 years or older, or under 60 but cannot have standard intensive chemotherapy due to age or other health problems, or you have refused that treatment.
- Your liver and kidneys must be working well enough (based on blood tests).
- You must be able to take care of most daily activities (ECOG score 0-2).
- You cannot have a very high white blood cell count (over 25,000) at the start of the study, but hydroxyurea can be used to lower it first.
- You cannot have had certain prior treatments like venetoclax, cladribine, or other similar drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This clinical trial tests a combination of three drugs: a liposomal form of mitoxantrone (a type of chemotherapy), cytarabine (another chemo drug), and venetoclax (a targeted therapy). The goal is to see if this combination is safe and works well for older adults (ages 60-70) who have just been diagnosed with AML and cannot have standard intensive chemotherapy.
This trial tests a new drug combination (VAC) for people with acute myeloid leukemia (AML) who did not improve after standard VA treatment. It is for those who cannot have strong chemotherapy due to age or health problems.
This study tests a combination of four drugs (venetoclax, homoharringtonine, azacitidine, and G-CSF) for people with newly diagnosed AML who cannot tolerate standard intensive chemotherapy. The goal is to see if this lower-intensity therapy can effectively treat the leukemia with fewer side effects.
This trial compares three chemotherapy combinations (HVA vs IA/DA or VA) for people with newly diagnosed high-risk acute myeloid leukemia (AML). It aims to find which treatment works better.
This trial tests whether a new combination (DEC3-VEN) works better than two other standard treatments for people with newly diagnosed acute myeloid leukemia (AML). The goal is to find the best initial therapy to help achieve remission.
This trial tests a combination of two chemotherapy regimens given in turns for people with newly diagnosed acute myeloid leukemia (AML) who cannot have standard intensive chemotherapy. The goal is to find a gentler but effective treatment option.
Hear when a new Newly Diagnosed trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.